Results 81 to 90 of about 30,536 (239)

Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer [PDF]

, 2017
Aberrant DNA methylation observed in cancer can provide survival benefits to cells by silencing genes essential for anti-tumor activity. DNA-demethylating agents such as Decitabine (DAC)/Azacitidine (AZA) activate otherwise silenced tumor suppressor ...
Attwood, Kristopher, Chatta, Gurkamal, Granger, Victoria, Gueron, Geraldine, Guru, Khurshid, Hu, Qiang, Johnson, Candace, Krishnan, Nithya, McNally, Lacey, Morrison, Carl, Pili, Roberto, Rak, Monika, Ramakrishnan, Swathi, Smit, Evelyn, Wang, Dan, Wang, Jianmin, Woloszynska-Read, Anna   +16 more
core   +3 more sources

Decitabine/Cedazuridine: First Approval

Drugs, 2020
A fixed dose oral combination (FDC) of decitabine and cedazuridine (Inqovi®), is being developed by Astex Pharmaceuticals (a subsidiary of Otsuka Pharmaceuticals) for the treatment of various cancers like myelodysplastic syndromes (MDS), chronic ...
Sohita Dhillon
semanticscholar   +1 more source

Clinical Response to Venetoclax and Decitabine in Acute Promyelocytic Leukemia With a Novel RARA-THRAP3 Fusion: A Case Report

Frontiers in Oncology, 2022
Variant acute promyelocytic leukemia (APL) showed quite different aspects, and the current treatments remained challenged at present. Venetoclax, a selective inhibitor of B-cell lymphoma 2 (BCL-2), is a small molecule that has been studied in several ...
B. Song, Xin Wang, X. Kong, Man Wang, L. Yao, Hongjie Shen, Jian Zhang, H. Qiu   +7 more
semanticscholar   +1 more source

2026 Update on the Management of Diffuse Large B‐Cell Lymphoma

American Journal of Hematology, EarlyView.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) is the most common type of NHL in the Western Hemisphere. It comprises a heterogenous group of lymphomas, with different biology and clinical prognoses. R‐CHP remains the backbone of therapy, and frontline therapeutic options in fit patients are pola‐R‐CHP and R‐CHOP, whereas elderly or frail/unfit ...
Elise A. Chong, Emily B. Tomasulo, Stefan K. Barta   +2 more
wiley   +1 more source

The nucleotidohydrolases DCTPP1 and dUTPase are involved in the cellular response to decitabine [PDF]

, 2016
Decitabine (5-aza-2acute;-deoxycytidine, aza-dCyd) is an anticancer drug used clinically for the treatment of myelodysplastic syndromes and acute myeloid leukemia that can act as a DNA-demethylating or genotoxic agent in a dose-dependent manner.
Horváth, András, Perez-Moreno, G., Requena, C. E., Ruiz-Perez, L. M., Vértessy, Beáta (Grolmuszné)   +4 more
core   +1 more source

Low-dose decitabine modulates myeloid-derived suppressor cell fitness via LKB1 in immune thrombocytopenia.

Blood, 2022
Myeloid-derived suppressor cells (MDSCs) are heterogeneous immature cells and natural inhibitors of adaptive immunity. Metabolic fitness of MDSC is fundamental for its suppressive activity towards effector T cells.
Xiaofei Ni, Lingjun Wang, Haoyi Wang, Tian-shu Yu, Jie Xie, Guo-sheng Li, Yanfeng Liu, Hai Zhou, Miao Xu, M. Hou, J. Peng, Yu Hou   +11 more
semanticscholar   +1 more source

Cold atmospheric plasma‐mediated tumor microenvironment remodeling for cancer treatment

BMEMat, EarlyView.
Schematic presentation of CAP‐mediated TME remodeling. This review summarizes recent efforts in cold atmospheric plasma (CAP) application in cancer treatment, highlighting the anticancer potential of CAP, molecular mechanisms, and future perspectives for further improvement and clinical translation.
Israr Khan, Qiujie Fang, Cao Fei, Ziyuan Wang, Zhaowei Chen, Guojun Chen, Zhiming Xu, Shu Xu, Zhitong Chen   +8 more
wiley   +1 more source

Development of a novel cell-based assay system EPISSAY for screening epigenetic drugs and liposome formulated decitabine [PDF]

, 2013
Extent: 11 p.BACKGROUND: Despite the potential of improving the delivery of epigenetic drugs, the subsequent assessment of changes in their epigenetic activity is largely dependent on the availability of a suitable and rapid screening bioassay.
Akkamsetty, Y., Callen, D., Ho, K., Kumar, R., Lim, S., Neilsen, P., Prestidge, C., Suetani, R., Walther, D., Wang, W.   +9 more
core   +2 more sources

Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases

American journal of hematology/oncology, 2021
Venetoclax (Ven) combined with a hypomethylating agent (HMA) has now emerged as an effective treatment regimen for acute myeloid leukemia, in both de novo and relapsed/refractory setting.
N. Gangat, P. Guglielmelli, Natasha Szuber, K. Begna, M. Patnaik, M. Litzow, A. Al-Kali, J. Foran, J. Palmer, H. Alkhateeb, M. Elliott, C. Hanson, A. Pardanani, F. Mannelli, A. Vannucchi, A. Tefferi   +15 more
semanticscholar   +1 more source

Genocopy of EVI1‐AML with paraneoplastic diabetes insipidus: PRDM16 overexpression by t(1;2)(p36;p21) and enhancer hijacking

British Journal of Haematology, EarlyView.
Summary Diabetes insipidus (DI) in patients with acute myeloid leukaemia (AML) and chromosome 3q alterations (EVI1/PRDM3/MECOM overexpression) constitutes a poorly understood paraneoplasia. A 44‐year‐old patient presented with clinical and morphological features of this syndrome but, surprisingly, disclosed the rare translocation t(1;2)(p36;p21), with ...
Julian List, Etienne Sollier, Fiona Brown‐Burke, Katherine Kelly, Dietmar Pfeifer, Valeria Shlyakhto, Kristina Maas‐Bauer, Milena Pantic, Christoph Plass, Michael Lübbert   +9 more
wiley   +1 more source